Variable | Mean, SD |
Age | 65.4, 10.9 |
n, % | |
Sex | |
Female | 9, 50.0% |
Male | 9, 50.0% |
Race | |
Black or African American | 10, 55.6% |
White | 0, 0% |
Asian | 0, 0% |
Other, unspecified | 5, 27.8% |
Decline or unavailable | 3, 16.7% |
Ethnicity | |
Hispanic or Latino | 6, 33.3% |
Non-Hispanic | 10, 55.6% |
Decline or unavailable | 2, 11.1% |
HbA1c | |
At goal ≤ 7 | 8, 44.4% |
Not at goal | 10, 55.6% |
Blood pressure | |
At goal ≤130/80 | 5, 27.8% |
Not at goal | 13, 72.2% |
eGFR categories | |
Category 1, eGFR ≥90 | 3, 16.7% |
Category 2, eGFR 60–89 | 9, 50.0% |
Category 3, eGFR 30–59 | 5, 26.3% |
Category 4, eGFR <30 | 1, 5.6% |
Degree of proteinuria | |
Moderate proteinuria | 6, 33.3% |
Severe proteinuria | 12, 66.7% |
Count of diabetes-related prescriptions* | |
0 | 1, 5.6% |
1 | 9, 50.0% |
2 | 3, 16.7% |
3 | 3, 16.7% |
4 | 2, 11.1% |
Count of hypertension-related prescriptions † | |
0 | 6, 33.3% |
1 | 7, 38.9% |
2 | 3, 16.7% |
3 | 1, 5.6% |
4 | 1, 5.6% |
Insurance type | |
Medicaid | 3, 16.7% |
Medicare | 10, 55.6% |
Commercial | 5, 27.8% |
Uninsured | 0, 0% |
*Count of prescriptions in EHR-defined pharmaceutical classes: insulins, biguanides, glucagon-like peptide 1 (GLP-1) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors; excludes SGLT2i prescription.
†Count of prescriptions in EHR-defined pharmaceutical classes: thiazide, loop and potassium-sparing diuretics, beta-blockers, calcium channel blockers, combined alpha and beta-blockers, alpha-antagonists, and hydralazine; excludes RAASi prescription.
eGFR, estimated glomerular filtration rate; EHR, electronic health record; GFR, glomerular filtration rate; HbA1C, hemoglobin A1C; RAASi, renin–angiotensin–aldosterone system inhibitors; SGLT2i, sodium-glucose cotransporter-2 inhibitors.